Article information
Full text is only aviable in PDF
REFERENCES
[1]
AF Barker.
Bronchiectasis.
N Engl J Med, 346 (2002), pp. 1383-1393
[2]
LM Reid.
Reduction in bronchial subdivision in bronchiectasis.
Thorax, 5 (1950), pp. 233-247
[3]
PJ Cole.
Inflammation: a two-edged sword–the model of bronchiectasis.
Eur J Respir Dis Suppl, 147 (1986), pp. 6-15
[4]
AP Watt, V Brown, J Courtney, M Kelly, L Garske, JS Elborn, et al.
Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis.
Thorax, 59 (2004), pp. 231-236
[5]
J Angrill, C Agusti, R de Celis, X Filella, A Rañó, M Elena, et al.
Bronchial inflammation and colonization in patients with clinically stable bronchiectasis.
Am J Respir Crit Care Med, 164 (2001), pp. 1628-1632
[6]
A Vilas, J Suárez.
Infección de bronquiectasias por Flavimonas oryzihabitans en paciente inmunocompetente.
Arch Bronconeumol, 40 (2004), pp. 384-385
[7]
Martínez-García MA, Perpiñá M, Román P, Soler JJ. Determinants of quality of life in patients with clinically stable bronchiectasis. Chest. In revision 2005.
[8]
MC Pasteur, SM Helliwell, SJ Houghton, SC Webb, JE Foweraker, RA Coulden, et al.
An investigation into causative factors in patients with bronchiectasis.
Am J Respir Crit Care Med, 162 (2000), pp. 1277-1284
[9]
KMA Perry, DS Kings.
Bronchiectasis: a study of prognosis based on a follow-up of 400 patients.
Am Rev Tuberc, 41 (1940), pp. 531-548
[10]
O Säynäjäkangäs, T Keistinen, T Tuuponen, SL Kivela.
Bronchiectasis in Finland: trends in hospital treatment.
Respir Med, 91 (1997), pp. 395-398
[11]
AF Barker, EJ Bardana.
Bronchiectasis: update of an orphan disease.
Am Rev Respir Dis, 137 (1988), pp. 969-978
[12]
GJ Brewer.
The orphan drug/orphan disease problem: has it been resolved?.
Pharm Int Dec, 5 (1984), pp. 297-300
[13]
KW Tsang, GL Tipoe.
Bronchiectasis: not an orphan disease in the East.
Int J Tuberc Lung Dis, (2004), pp. 691-702
[14]
P Grenier, MP Cordeau, C Beigelman.
High resolution computed tomography of the airways.
J Thorac Imag, 8 (1993), pp. 213-229
[15]
MB Nicotra, M Rivera, AM Dale, R Shepherd, R Carter.
Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort.
Chest, 108 (1995), pp. 955-961
[16]
AF Barker.
Treatment of bronchiectasis.
[17]
AJ Crockett, JM Cranston, KM Latimer, JH Alpers.
Mucolytics for bronchiectasis (Cochrane review).
The Cochrane Library, Issue 4, John Wiley and Sons, Ltd., (2004),
[18]
AF Barker, L Couch, SB Fiel, MH Gotfried, J Ilowite, KC Meyer, et al.
Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis.
Am J Respir Crit Care Med, 162 (2000), pp. 481-485
[19]
DJ Evans, M Greenstone.
Long-term antibiotics in the management of non-CF bronchiectasis — do they improve outcome?.
Respir Med, 97 (2003), pp. 851-858
[20]
Hospital Episode Statistics 2002-2003. Department of Health. NHLBI.
[21]
T Keistinen, O Säynäjäkangäs, T Tuuponen, SL Kivela.
Bronchiectasis: an orphan disease with a poorly-understood prognosis.
Eur Respir J, 10 (1997), pp. 2784-2787
[22]
S Loukides, I Horvath, T Wodehouse, PJ Cole, PJ Barnes.
Elevated levels of expired breath hydrogen peroxide in bronchiectasis.
Am J Respir Crit Care Med, 158 (1998), pp. 991-994
[23]
I Horvath, S Loukides, T Wodehouse, SA Kharitonov, PJ Cole, PJ Barnes.
Increased levels of exhaled carbon monoxide in bronchiectasis: a new marker of oxidative stress.
Thorax, 53 (1998), pp. 867-870
[24]
SA Kharitonov, AU Wells, BJ O'Connor, PJ Cole, D Hansell, RB Logan-Sinclair, et al.
Elevated levels of exhaled nitric oxide in bronchiectasis.
Am J Respir Crit Care Med, 151 (1995), pp. 1889-1893
[25]
L Zheng, G Tipoe, WK Lam, JC Ho, I Shum, GC Ooi, et al.
Endothelin-1 in stable bronchiectasis.
Eur Respir J, 16 (2000), pp. 146-149
[26]
SC Chan, DK Shum, MS Ip.
Sputum sol neutrophils elastase activity in bronchiectasis: differential modulation by syndecam-1.
Am J Respir Crit Care Med, 168 (2003), pp. 192-198
[27]
RE Sheehan, AU Wells, SJ Copley, SR Desai, SJ Howling, PJ Cole, et al.
A comparison of serial computed tomography and functional change in bronchiectasis.
Eur Respir J, 20 (2002), pp. 581-587
[28]
NG Koulouris, S Retsou, E Kosmas, K Dimakou, K Malagari, G Mantzikopoulos, et al.
Tidal expiratory flow limitation, dyspnea and exercise capacity in patients with bilateral bronchiectasis.
Eur Respir J, 21 (2003), pp. 743-748
[29]
MA Martínez-García, M Perpiñá, P Román, JJ Soler.
Consistencia interna y validez de la versión española del St. George's Respiratory Questionnaire para su uso en pacientes afectos de bronquiectasias clínicamente estables.
Arch Bronconeumol, 41 (2005), pp. 110-117
[30]
IS Patel, I Vlahos, TMA Wilkinson, SJ Lloyd-Owen, GC Donaldson, M Wilks, et al.
Bronchiectasis, exacerbations indices, and inflammation in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 170 (2004), pp. 400-407
[31]
RE Kanner, NR Anthonisen, JE Connett.
Lower respiratory illnesses promote FEV1 decline in current smokers but not exsmokers with mild chronic obstructive lung disease: results from the Lung Health Study.
Am J Respir Crit Care Med, 164 (2001), pp. 358-364
[32]
TMA Wilkinson, IS Patel, M Wilks, GC Donaldson, JA Wedzicha.
Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med, 167 (2003), pp. 1090-1095
Copyright © 2005. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
